Angiotensin-II Receptor Blockers (ARB) - Revision history

Lazy at 08:23, 18 January 2025

2025-01-18T08:23:12Z

← Older revision		Revision as of 01:23, 18 January 2025
Line 60:		Line 60:

	See Chapter 13 for a discussion of Angiotensin system inhibitors plus Avastin		See Chapter 13 for a discussion of Angiotensin system inhibitors plus Avastin
	}}		\|overview=Angiotensin-II Receptor Blockers (ARBs), initially approved for hypertension, are being investigated for their potential to reduce vasogenic edema and steroid requirements in glioblastoma patients, showing promising effects in retrospective studies despite no direct survival benefits reported. Ongoing research, including a randomized phase 3 trial, aims to further explore the supportive role of ARBs in glioblastoma management.}}

Lazy at 19:10, 25 December 2024

2024-12-25T19:10:00Z

@@ Line 9: / Line 9: @@
 |usefulness_rating=3
 |notes=ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.
-|treatment_category=Hormones
+|treatment_category=Hormones and Cancer Therapy
 |links=
 |toxicity_level=2
 |toxicity_explanation=Angiotensin-II Receptor Blockers, primarily used for high blood pressure, have been repurposed for cancer studies, specifically for reducing swelling around brain tumors and lowering the need for steroids. Common side effects can include dizziness, low blood pressure, and alterations in kidney function. However, these are generally mild and manageable, hence the relatively low toxicity rating. While these drugs have shown potential in improving some symptoms, their impact on tumor growth or survival rate is still under investigation.
 }}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:35:55Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:35, 12 November 2024
Line 9:		Line 9:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.		\|notes=ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.
	\|~~category~~=Hormones		\|treatment_category=Hormones
	\|links=		\|links=
	\|toxicity_level=2		\|toxicity_level=2
	\|toxicity_explanation=Angiotensin-II Receptor Blockers, primarily used for high blood pressure, have been repurposed for cancer studies, specifically for reducing swelling around brain tumors and lowering the need for steroids. Common side effects can include dizziness, low blood pressure, and alterations in kidney function. However, these are generally mild and manageable, hence the relatively low toxicity rating. While these drugs have shown potential in improving some symptoms, their impact on tumor growth or survival rate is still under investigation.		\|toxicity_explanation=Angiotensin-II Receptor Blockers, primarily used for high blood pressure, have been repurposed for cancer studies, specifically for reducing swelling around brain tumors and lowering the need for steroids. Common side effects can include dizziness, low blood pressure, and alterations in kidney function. However, these are generally mild and manageable, hence the relatively low toxicity rating. While these drugs have shown potential in improving some symptoms, their impact on tumor growth or survival rate is still under investigation.
	}}		}}

Lazy at 16:56, 27 March 2024

2024-03-27T16:56:21Z

← Older revision		Revision as of 09:56, 27 March 2024
Line 11:		Line 11:
	\|category=Hormones		\|category=Hormones
	\|links=		\|links=
			\|toxicity_level=2
			\|toxicity_explanation=Angiotensin-II Receptor Blockers, primarily used for high blood pressure, have been repurposed for cancer studies, specifically for reducing swelling around brain tumors and lowering the need for steroids. Common side effects can include dizziness, low blood pressure, and alterations in kidney function. However, these are generally mild and manageable, hence the relatively low toxicity rating. While these drugs have shown potential in improving some symptoms, their impact on tumor growth or survival rate is still under investigation.
	}}		}}

Lazy at 04:45, 26 March 2024

2024-03-26T04:45:07Z

← Older revision		Revision as of 21:45, 25 March 2024
Line 7:		Line 7:
	\|OS_with=Not specified; studies have focused on steroid requirements and edema control		\|OS_with=Not specified; studies have focused on steroid requirements and edema control
	\|PFS_with=Not specified; primary focus has been on edema reduction and potentially improved quality of life		\|PFS_with=Not specified; primary focus has been on edema reduction and potentially improved quality of life
	\|usefulness_rating=~~Investigational (specific rating not provided due to mixed outcomes and study focuses)~~		\|usefulness_rating=3
	\|notes=ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.		\|notes=ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.
	\|category=Hormones		\|category=Hormones
	\|links=		\|links=
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Angiotensin-II Receptor Blockers (ARB) |FDA_approval=Yes (for hypertension; repurposed for cancer studies) |used_for=Investigational use in glioblastoma for potential reduction of vasogenic edema and steroid-sparing effects |clinical_trial_phase=Retrospective Studies |common_side_effects=Varies by specific ARB; can include dizziness, hypotension, and renal function alteration |OS_with=Not specified; studies have focused on steroid requirements..."

2024-03-24T13:27:35Z

Created page with "{{TreatmentInfo |drug_name=Angiotensin-II Receptor Blockers (ARB) |FDA_approval=Yes (for hypertension; repurposed for cancer studies) |used_for=Investigational use in glioblastoma for potential reduction of vasogenic edema and steroid-sparing effects |clinical_trial_phase=Retrospective Studies |common_side_effects=Varies by specific ARB; can include dizziness, hypotension, and renal function alteration |OS_with=Not specified; studies have focused on steroid requirements..."

New page

{{TreatmentInfo
|drug_name=Angiotensin-II Receptor Blockers (ARB)
|FDA_approval=Yes (for hypertension; repurposed for cancer studies)
|used_for=Investigational use in glioblastoma for potential reduction of vasogenic edema and steroid-sparing effects
|clinical_trial_phase=Retrospective Studies
|common_side_effects=Varies by specific ARB; can include dizziness, hypotension, and renal function alteration
|OS_with=Not specified; studies have focused on steroid requirements and edema control
|PFS_with=Not specified; primary focus has been on edema reduction and potentially improved quality of life
|usefulness_rating=Investigational (specific rating not provided due to mixed outcomes and study focuses)
|notes=ARBs, primarily used for hypertension, have shown potential in reducing steroid dose requirements and peri-tumoral edema in glioblastoma patients in retrospective studies. While no direct survival benefit has been observed, the reduction in steroid dosage and control of edema suggest a potential supportive role in glioblastoma management. Further research, including a randomized phase 3 trial in France, is exploring the impact of ARBs like losartan on glioblastoma treatment outcomes.
|category=Hormones
|links=
}}